Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02022020 · ClinicalTrials.gov registry record
Management of Gastrointestinal and Urogenital (GI/GU) Bleedings in Atrial Fibrillation Patients Using Pradaxa
A clinical trial of Atrial Fibrillation, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- 220
- Enrollment target
- 20
- Study locations
NCT02022020: Completed study of Atrial Fibrillation, sponsored by Boehringer Ingelheim.
NCT02022020 is a study of Atrial Fibrillation that has completed, run by Boehringer Ingelheim. The registered enrollment target is 220 participants, below the 2,996-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (93% lower). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02022020, a study of Atrial Fibrillation, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- 220 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is being conducted to collect data on the management of gastrointestinal and urogenital bleeding events occurring in patients with atrial fibrillation taking dabigatran etexilate.
Primary Outcome
Percentages of patients with index event safety outcomes (ongoing/resolved/deceased) at the time of their hospital discharge/release. Emergency Department/Room (ED/ER). Bleeding status at the time of discharge were classified by the principal investigator, using medical record information and medical opinion, as: * Ongoing, if symptoms of bleeding not completely resolved at time of discharge; * Deceased in case of death; * Resolved otherwise.
Conditions Studied
Study Locations (20)
Virginia
- Boehringer Ingelheim Investigational Site - Charlottesville
- Boehringer Ingelheim Investigational Site - Norfolk
- Boehringer Ingelheim Investigational Site - Roanoke
Florida
- Boehringer Ingelheim Investigational Site - Orlando
- Boehringer Ingelheim Investigational Site - Tampa
Missouri
- Boehringer Ingelheim Investigational Site - Chesterfield
- Boehringer Ingelheim Investigational Site - St Louis
New York
- Boehringer Ingelheim Investigational Site - New York
- Boehringer Ingelheim Investigational Site - Staten Island
Colorado
- Boehringer Ingelheim Investigational Site - Aurora
Connecticut
- Boehringer Ingelheim Investigational Site - New Britain
Louisiana
- Boehringer Ingelheim Investigational Site - New Orleans
Massachusetts
- Boehringer Ingelheim Investigational Site - Springfield
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2014-01 |
| Est. Completion | 2015-10 |
What the finished NCT02022020 record still lists
NCT02022020 is an observational study that tracks outcomes without assigning an intervention. The registered 220 participants enrollment target is mid-sized for trials with a published cap, below the 2,996-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Atrial Fibrillation appearing as the primary indexed condition, and to 0 interventions.
NCT02022020 names 20 study sites across 15 states, led by Virginia, Florida, Missouri.
Frequently Asked Questions
What is clinical trial NCT02022020 about?
NCT02022020 is a clinical study titled "Management of Gastrointestinal and Urogenital (GI/GU) Bleedings in Atrial Fibrillation Patients Using Pradaxa". This study is being conducted to collect data on the management of gastrointestinal and urogenital bleeding events occurring in patients with atrial fibrillation taking dabigatran etexilate.
What is the current status of trial NCT02022020?
This trial is currently completed. The enrollment target is 220 participants. The study started on 2014-01. Estimated completion is 2015-10.
What conditions does trial NCT02022020 study?
This clinical trial studies the following conditions: Atrial Fibrillation.
Who is sponsoring clinical trial NCT02022020?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02022020 being conducted?
This trial has 20 study locations across Colorado, Connecticut, Florida, Louisiana, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atrial Fibrillation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02022020's enrollment target sits among peer trials
220 98th of 202 higher than 104 of 202 other Atrial Fibrillation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atrial Fibrillation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Amiodarone for the Prevention of Atrial Fibrillation After Minimally Invasive Esophagectomy in Patients With Esophageal Cancer
RECRUITING · Phase 2
-
The Dynamics of Human Atrial Fibrillation
RECRUITING
-
Renal Denervation + PVI vs PVI Alone for Persistent AF
RECRUITING · NA
-
Pericardiotomy in Cardiac Surgery
RECRUITING · NA
-
CellFX® Nanosecond Pulsed Field Ablation (nsPFA)™ Cardiac Surgery Clamp System to Treat Atrial Fibrillation
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00920972 · 220 participants · Phase 1
Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases
- NCT01851642 · 220 participants
Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs
- NCT02582021 · 220 participants
WISE CVD - Continuation (WISE HFpEF)
- NCT04067830 · 220 participants · Phase 2
Respiratory Muscle Training Before Surgery in Preventing Lung Complications in Patients With Stage I-IIIB Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia